Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacific Biosciences of California, Inc. on August 6, 2020. The filing primarily addresses significant changes in corporate leadership and governance effective September 14, 2020.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive appointments and compensation arrangements.
Material Changes
- CEO Appointment: Christian O. Henry was appointed as Chief Executive Officer, effective September 14, 2020, succeeding Dr. Michael Hunkapiller.
- Leadership Transition: Dr. Hunkapiller will retire from an active operating role at the end of 2020, transitioning to Senior Fellow focused on technology development while remaining on the Board.
- Board Changes: Christian O. Henry will step down as Chairman of the Board. Dr. John F. Milligan was appointed as the new Chairman of the Board.
- CFO Search: The Board continues its search for a new Chief Financial Officer.
Compensation and Management Commentary
Mr. Henry's employment agreement includes the following key terms starting September 14, 2020:
- Base Salary: $650,000 annually.
- Bonus: Target bonus opportunity equal to 100% of base salary, subject to performance goals.
- Stock Options: Grant of options to purchase 1,500,000 shares. Vesting schedule: 25% on the 1-year anniversary, with the remainder vesting monthly (1/48th per month).
- Restricted Stock Units (RSUs): Grant of 750,000 shares. Vesting schedule: 25% on each anniversary of the grant date.
- Severance: Benefits substantially similar to those previously provided to Dr. Hunkapiller in the event of termination without cause or resignation for good reason.
Investor Verification Checklist
- Verify the full text of the Employment Agreement filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2020.
- Review the press release dated August 7, 2020 (Exhibit 99.1) for additional context on the leadership transition.
- Monitor future filings for the appointment of a new Chief Financial Officer.
- Confirm the specific performance goals tied to Mr. Henry's annual bonus in subsequent disclosures.